R. Huijgen

发表

Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients: A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE Studies

J. Kastelein, M. Bots, C. Ballantyne, 2010, Circulation. Cardiovascular imaging.

Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk[S]

J. Kastelein, F. Wijburg, B. Hutten, 2013, Journal of Lipid Research.

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia[S]

J. Kastelein, G. Lambert, B. Hutten, 2012, Journal of Lipid Research.

Assessment of Carotid Atherosclerosis in Normocholesterolemic Individuals With Proven Mutations in the Low-Density Lipoprotein Receptor or Apolipoprotein B Genes

M. Trip, J. Kastelein, E. de Groot, 2011, Circulation. Cardiovascular genetics.

Factor VIII deficiency does not protect against atherosclerosis

H. Büller, E. Groot, P. Verhamme, 2012, Journal of thrombosis and haemostasis : JTH.

Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

J. Kastelein, B. Imholz, E. Stroes, 2018, Journal of clinical lipidology.

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.

P. Barter, J. Kastelein, S. Boekholdt, 2012, Journal of the American College of Cardiology.

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.

P. Barter, J. Kastelein, S. Boekholdt, 2012, Journal of the American College of Cardiology.

Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal

E. Sijbrands, J. Kastelein, B. Hutten, 2010, PloS one.

UvA-DARE ( Digital Academic Repository ) Two Years after Molecular Diagnosis of Familial Hypercholesterolemia : Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment

E. Sijbrands, B. Hutten, M. N. Vissers, 2010 .

Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance

E. Sijbrands, J. Kastelein, S. Middeldorp, 2008, European Journal of Human Genetics.

Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance

E. Sijbrands, J. Kastelein, S. Middeldorp, 2008, European Journal of Human Genetics.

Discriminative Ability of LDL-Cholesterol to Identify Patients With Familial Hypercholesterolemia: A Cross-Sectional Study in 26 406 Individuals Tested for Genetic FH

J. Kastelein, B. Hutten, M. N. Vissers, 2012, Circulation. Cardiovascular genetics.

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

J. Kastelein, B. Imholz, F. Visseren, 2010, Atherosclerosis.

Venous thrombosis is associated with hyperglycemia at diagnosis: a case–control study

H. Büller, J. DeVries, J. Hoekstra, 2009, Journal of thrombosis and haemostasis : JTH.

Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.

A. Grefhorst, E. Stroes, G. Hovingh, 2020, Atherosclerosis.

Risk Factors for Cholecystectomy After Laparoscopic Roux-En-Y Gastric Bypass

V. Gerdes, Y. Acherman, A. W. van de Laar, 2019, Obesity Surgery.

LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.

D. Blom, A. Marais, R. Huijgen, 2018, Atherosclerosis.

Increased coagulation factor VIII activity in patients with familial hypercholesterolemia.

J. Kastelein, J. Meijers, R. Huijgen, 2011, Blood.

UvA-DARE ( Digital Academic Repository ) Familial hypercholesterolemia : the Dutch approach

J. Kastelein, B. Imholz, S. Middeldorp, 2012 .

Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program.

J. Kastelein, F. Wijburg, B. Hutten, 2012, The Journal of pediatrics.

Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children

J. Kastelein, F. Wijburg, B. Hutten, 2011, Circulation.

Interpretation of laboratory results after gastric bypass surgery: the effects of weight loss and time on 30 blood tests in a 5-year follow-up program.

M. Nieuwdorp, V. Gerdes, Y. Acherman, 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

The impact of LDLR function on fibroblast growth factor 21 levels.

K. Rye, K. Ong, G. Hovingh, 2015, Atherosclerosis.

Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality.

E. Sijbrands, J. Kastelein, J. Versmissen, 2011, Atherosclerosis.

Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.

J. Kastelein, S. Martin, G. Hovingh, 2016, Atherosclerosis.

Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study.

E. Fliers, H. Büller, V. Gerdes, 2010, Blood.

Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study

J. Kastelein, B. Hutten, M. N. Vissers, 2012, European Journal of Human Genetics.

Determining When to Add Nonstatin Therapy: A Quantitative Approach.

Jennifer G. Robinson, M. Pencina, J. Robinson, 2016, Journal of the American College of Cardiology.

Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis

M. Durán, J. Kastelein, E. Stroes, 2012, Clinical genetics.

Hip surgery sequentially induces stress hyperglycaemia and activates coagulation.

J. DeVries, J. Hermanides, M. Levi, 2009, The Netherlands journal of medicine.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach

A. Hofman, A. Uitterlinden, A. Zwinderman, 2014, European Journal of Human Genetics.

Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance

E. Sijbrands, J. Kastelein, S. Middeldorp, 2008, European Journal of Human Genetics.

Quality Assessment of the Genetic Test for Familial Hypercholesterolemia in The Netherlands

Peter de Knijff, John J. P. Kastelein, P. de Knijff, 2013, Cholesterol.

Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants.

J. Kastelein, John J P Kastelein, J. Defesche, 2012, European heart journal.

Discriminative Ability of LDL-Cholesterol to Identify Patients With Familial HypercholesterolemiaClinical Perspective

J. Kastelein, B. Hutten, M. N. Vissers, 2012 .

Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.

S. Gabriel, S. Kathiresan, R. Do, 2012, European heart journal.

Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL‐Cl Levels

J. Kastelein, G. Hovingh, J. Defesche, 2012, Human mutation.

Functionality of sequence variants in the genes coding for the low‐density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia

J. Kastelein, John J P Kastelein, B. Hutten, 2010, Human mutation.

Familial hypercholesterolemia: current treatment and advances in management

J. Kastelein, B. Hutten, P. Lansberg, 2008, Expert review of cardiovascular therapy.

Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.

D. Blom, A. Marais, César Martín, 2020, Arteriosclerosis, thrombosis, and vascular biology.

Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.

J. Kastelein, G. Hovingh, J. Kastelein, 2016, Journal of the American College of Cardiology.

Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes

J. Kastelein, B. Hutten, J. Defesche, 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Increased carotid intima-media thickness predicts cardiovascular events in aortic coarctation.

B. Mulder, M. Groenink, H. Vliegen, 2014, International journal of cardiology.

Adherence to Statin Treatment in Patients with Familial Hypercholesterolemia: a Dynamic Prediction Model

J. Kastelein, E. Stroes, M. Hof, 2022, Journal of Clinical Lipidology.

PCSK9 inhibition: the way forward in the treatment of dyslipidemia

J. Kastelein, R. Stoekenbroek, R. Huijgen, 2015, BMC Medicine.

Abstract: P841 NON-FUNCTIONALITY OF THREE LDL-R AND APOB GENE MUTATIONS THAT WERE ASSUMED TO CAUSE FAMILIAL HYPERCHOLESTEROLEMIA

J. Kastelein, B. Hutten, J. Defesche, 2009 .

Abstract: P870 IDENTIFICATION OF APOB AND PCSK9 MUTATIONS CAUSING A NON-ADH PHENOTYPE IN MOLECULAR DIAGNOSED ADH PATIENTS

J. Kastelein, J. Defesche, R. Huijgen, 2009 .

Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality.

E. Sijbrands, J. Kastelein, J. Versmissen, 2011, Atherosclerosis.

Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes

J. Kastelein, B. Hutten, J. Defesche, 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

UvA-DARE ( Digital Academic Repository ) Measure for measure : consequences , detection and treatment of hyperglycaemia

J. DeVries, J. Hermanides, J. Hoekstra, 2010 .

Determining When to Add Nonstatin Therapy: A Quantitative Approach.

Jennifer G. Robinson, M. Pencina, J. Kastelein, 2016, Journal of the American College of Cardiology.

Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study.

E. Fliers, H. Büller, V. Gerdes, 2010, Blood.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

J. Kastelein, B. Imholz, F. Visseren, 2010, Atherosclerosis.

Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal

J. Kastelein, B. Hutten, M. N. Vissers, 2010, PloS one.

Venous thrombosis is associated with hyperglycemia at diagnosis: a case–control study

H. Büller, J. DeVries, J. Hoekstra, 2009, Journal of thrombosis and haemostasis : JTH.

Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study

M. Netea, J. Meer, S. Alonso, 2012, European Journal of Human Genetics.

Glucose variability is associated with ICU mortality

J. DeVries, J. Hermanides, J. Hoekstra, 2010 .